AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01814332
Drug: GSK561679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK561679, oral administration, 350mg/day, 6 week administration
Trial: NCT01814332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo compound treatment for comparison with IP
Trial: NCT03569007
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enteric-coated beads in gelatin capsules
Trial: NCT00001857
Drug: BG9588
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172742
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 2-093 1200 mg once-daily
Trial: NCT02172742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT03099863
Drug: Cystoscopic Fluid containing Neosporin G. U. Irrigant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
Trial: NCT03099863
Drug: Cystoscopic Fluid/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline cystoscopic fluid
Trial: NCT00580294
Drug: Oxymorphone
RxNorm normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV PO
Trial: NCT01491932
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFQ056 will be supplied as oral capsules.
Trial: NCT00043680
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02196558
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005898
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03622931
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03622931
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618395
Drug: SPARC001A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618395
Drug: SPARC001B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618395
Drug: Reference001 - Hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen
Trial: NCT01721330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 6 weeks
Trial: NCT00165347
Drug: PTK787/ZK222584
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02235012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Trial: NCT02106559
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo PDT
Trial: NCT02636322
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02636322
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02326090
Drug: cis-UCA ophthalmic solution 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02326090
Drug: cis-UCA ophthalmic solution 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02326090
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00513864
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one time dose - 2mg/kg PO
Trial: NCT00001082
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablet taken orally daily
Trial: NCT02618187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618187
Drug: Placebo Pre-Treat
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03488485
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAAs given in patients with viremic chronic hepatitis C
Trial: NCT02993432
Drug: prostaglandin of the clinician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
Trial: NCT00279513
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00393146
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug
Trial: NCT01981928
Drug: ASP7962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01981928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01444170
Drug: placebo sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02390375
Drug: DW-0929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/10mg
Trial: NCT02390375
Drug: DW-0929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/10mg
Trial: NCT02390375
Drug: DW-0929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/10mg
Trial: NCT02390375
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg F/U study: DW-0929 5/10mg
Trial: NCT02390375
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg F/U study: DW-0929 10/10mg
Trial: NCT02390375
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg F/U study: DW-0929 20/10mg
Trial: NCT00372320
Drug: AdhAQP1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03055507
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Addition of ibuprofen to standard pain regimen.
Trial: NCT03055507
Drug: Acetaminophen 650 mg
RxNorm normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic provided post-operatively to patients undergoing sinus surgery
Trial: NCT02369250
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin, is a statin group of drug.
Trial: NCT02315196
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00699166
Drug: DNK333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg and 100 mg oral doses, each taken twice daily
Trial: NCT01783236
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg IV Ofirmev given every six hours for a total of four doses.
Trial: NCT01783236
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
Trial: NCT03934307
Drug: ALN-AGT01-Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
Trial: NCT04193527
Drug: DaTSCAN™ Ioflupane (123I) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
Trial: NCT04551924
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
Trial: NCT00887588
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, 100 mg and 200 mg tablets
Trial: NCT00887588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to LCZ696 and Valsartan
Trial: NCT03335566
Drug: Sonazoid™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
Trial: NCT03335566
Drug: SonoVue®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of SonoVue® 2.4 mL as I.V. injection.
Trial: NCT03721965
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
Trial: NCT03568071
Drug: MOR 106
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
Trial: NCT03568071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
Trial: NCT04488094
Drug: [18F]FSPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
Trial: NCT00291226
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine 0.4 g/kg bid
Trial: NCT00291226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00557102
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00557102
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00127933
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 825mg/m2 po bid on days 1-14 of each 3 week cycle
Trial: NCT03753477
Drug: Sevikar and Crestor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
Trial: NCT00498485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
Trial: NCT00066937
Drug: Benztropine Oral Product
RxNorm normalized name: benztropine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
Trial: NCT02027194
Drug: Cure-Allergic Rhinitis Syrup
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered one bottle for two weeks to the participants twice
Trial: NCT02027194
Drug: Yu-ping-fung San
RxNorm normalized name: Fung-A-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered one bottle for 2-week usage to the participants twice
Trial: NCT02027194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
Trial: NCT02470767
Drug: Direct Oral Anticoagulant (DOAC)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment pattern following the summary of product characteristics
Trial: NCT03111732
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
Trial: NCT04679818
Drug: Routine opioid management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
Trial: NCT03315559
Drug: [14C]-GSK2269557 IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
Trial: NCT03315559
Drug: [14C]-GSK2269557 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
Trial: NCT02767245
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine IV 100 mg/day
Trial: NCT00328809
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone administered to ESRD patients at low dose
Trial: NCT00775086
Drug: norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04062331
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
Trial: NCT01472835
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used for analgesia and as a sedative
Trial: NCT01098578
Drug: Floseal
RxNorm normalized name: Floseal Hemostatic Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received 1 syringe of Floseal as treatment for posterior epistaxis.
Trial: NCT04002427
Drug: Intravenous Infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
Trial: NCT04002427
Drug: Inhaled dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single inhalation on one occasion.
Trial: NCT01796444
Drug: Adjuvant Systemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
Trial: NCT03358290
Drug: JTE-051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug tablets containing JTE-051
Trial: NCT03358290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance to the active drug tablets
Trial: NCT00860964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, calcium 900mg/d, VitD200iu/d and exercise
Trial: NCT00726804
Drug: Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
Trial: NCT01112267
Drug: Tramadol HCl/acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
Trial: NCT01112267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
Trial: NCT01112267
Drug: Tramadol HCl/acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
Trial: NCT01112267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
Trial: NCT03889795
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin oral pill will be taken daily in the evening.
Trial: NCT01404325
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: centre specific CNI-based triple drug immunosuppression
Trial: NCT00060385
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00060385
Drug: EPOCH regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00060385
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00060385
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02733588
Drug: G-Pump™ (glucagon infusion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
Trial: NCT03012945
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
Trial: NCT03352206
Drug: 3 drug dose - IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Trial: NCT01204164
Drug: TG02 citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG02 citrate capsules given orally.
Trial: NCT03593408
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered for sedation management per hospital protocol
Trial: NCT04290676
Drug: DEXYCU (dexamethasone intraocular suspension) 9%.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
Trial: NCT00556712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily
Trial: NCT00284934
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284934
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At a dose of at least 5 mg/day.
Trial: NCT02885922
Drug: anti-diabetic drug
RxNorm normalized name: INVESTIGATIONAL ANTI-DIABETIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on anti-diabetic drug in type 2 diabetic patients
Trial: NCT00326495
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
Trial: NCT01389284
Drug: Naproxen Sodium ER (BAYH6689)
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
Trial: NCT01389284
Drug: Naproxen Sodium IR (Aleve, BAYH6689)
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
Trial: NCT01389284
Drug: Naproxen Sodium ER Placebo
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
Trial: NCT01389284
Drug: Naproxen Sodium IR Placebo
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
Trial: NCT02216877
Drug: Mablet 360 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02216877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00784927
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes